Alaunos Therapeutics (TCRT) Total Current Liabilities (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Total Current Liabilities came in at $595000.0 in Q1 2026, down 43.97% YoY from $1.1 million in Q1 2025, and down 26.81% on a QoQ basis from $813000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Total Current Liabilities (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Total Current Liabilities data on file, last reported at $595000.0 in Q1 2026.
- Quarterly Total Current Liabilities fell 43.97% year-over-year to $595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $595000.0 (down 43.97% YoY) and the FY2025 annual result came in at $813000.0, up 17.49% from the prior year.
- Total Current Liabilities slipped to $595000.0 in Q1 2026, from $813000.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $32.9 million in Q3 2022 to a low of $595000.0 in Q1 2026.
- A 5-year average of $8.3 million and a median of $1.2 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 96.98% — and 2024, when it plunged 92.73%.
- Tracing TCRT's Total Current Liabilities over 5 years: stood at $24.2 million in 2022, then sank by 91.91% to $2.0 million in 2023, then slumped by 64.62% to $692000.0 in 2024, then increased by 17.49% to $813000.0 in 2025, then decreased by 26.81% to $595000.0 in 2026.
- The last three Total Current Liabilities figures came in at $595000.0 (Q1 2026), $813000.0 (Q4 2025), and $921000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 630.93 Mn |
| 10 | Alaunos Therapeutics | 4.26 Mn | 4.13 Mn | - | 864,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 595,000.00 |
| Dec 31, 2025 | 813,000.00 |
| Sep 30, 2025 | 921,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 692,000.00 |
| Sep 30, 2024 | 826,000.00 |
| Jun 30, 2024 | 907,000.00 |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 4.68 Mn |
| Jun 30, 2023 | 5.05 Mn |
| Mar 31, 2023 | 17.06 Mn |
| Dec 31, 2022 | 24.17 Mn |
| Sep 30, 2022 | 32.87 Mn |
| Jun 30, 2022 | 26.78 Mn |
| Mar 31, 2022 | 21.23 Mn |
| Dec 31, 2021 | 16.04 Mn |
| Sep 30, 2021 | 28.17 Mn |
| Jun 30, 2021 | 13.59 Mn |